{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:07:35Z","timestamp":1777518455507,"version":"3.51.4"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,4,9]]},"DOI":"10.1007\/s13318-018-0513-7","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T14:58:00Z","timestamp":1538578680000},"page":"139-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis"],"prefix":"10.1007","volume":"44","author":[{"given":"Zorica","family":"Jovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejana","family":"Ru\u017ei\u0107 Ze\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Milovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sr\u0111an","family":"Stefanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Foli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Milovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kosti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"issue":"4","key":"513_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/jhin.2002.1278","volume":"53","author":"DP Kontoyiannis","year":"2003","unstructured":"Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect. 2003;53(4):243\u201358.","journal-title":"J Hosp Infect"},{"issue":"165","key":"513_CR2","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"GD Brown","year":"2012","unstructured":"Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.","journal-title":"Sci Transl Med"},{"issue":"5","key":"513_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tim.2010.02.004","volume":"18","author":"DW Denning","year":"2010","unstructured":"Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 2010;18(5):195\u2013204.","journal-title":"Trends Microbiol"},{"issue":"18","key":"513_CR4","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","volume":"71","author":"C Lass-Florl","year":"2011","unstructured":"Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs. 2011;71(18):2405\u201319.","journal-title":"Drugs"},{"issue":"4","key":"513_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):433\u201342.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"513_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","volume":"5","author":"HA Torres","year":"2005","unstructured":"Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5(12):775\u201385.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"513_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/phar.1652","volume":"35","author":"JM Rybak","year":"2015","unstructured":"Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037\u201351.","journal-title":"Pharmacotherapy"},{"issue":"17","key":"513_CR8","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","volume":"76","author":"M Shirley","year":"2016","unstructured":"Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76(17):1647\u201357.","journal-title":"Drugs."},{"issue":"8","key":"513_CR9","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1128\/AAC.48.8.3107-3111.2004","volume":"48","author":"M Cuenca-Estrella","year":"2004","unstructured":"Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother. 2004;48(8):3107\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"513_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","volume":"68","author":"I Scholz","year":"2009","unstructured":"Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"513_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"513_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-017-0445-7","author":"KJ Wilby","year":"2017","unstructured":"Wilby KJ. A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole. Eur J Drug Metab Pharmacokinet. 2017. https:\/\/doi.org\/10.1007\/s13318-017-0445-7.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"513_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","volume":"27","author":"D Lev\u00eaque","year":"2006","unstructured":"Lev\u00eaque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2006;27(4):274\u201384.","journal-title":"Int J Antimicrob Agents"},{"key":"513_CR14","unstructured":"European Medicines Agency. Vfend: summary of product characteristics. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000387\/human_med_001135.jsp&mid=WC0b01ac058001d124. Cited 8 Mar 2018."},{"key":"513_CR15","doi-asserted-by":"crossref","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Infectious Diseases Society of America, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56\u201393.","DOI":"10.1093\/cid\/cir073"},{"issue":"Suppl 1","key":"513_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","volume":"10","author":"JA Maertens","year":"2004","unstructured":"Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(Suppl 1):1\u201310.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"513_CR17","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","volume":"46","author":"L Purkins","year":"2002","unstructured":"Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"513_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol. 2003;56(Suppl 1):10\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"513_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijantimicag.2016.10.010","volume":"49","author":"A Veringa","year":"2017","unstructured":"Veringa A, Geling S, Span LFR, Vermeulen KM, Zijlstra JG, van derWerf TS, Kosterink JGW, Jan-Willem C, Alffenaar JWC. Bioavailability of voriconazole in hospitalised patients. Int J Antimicrob Agents. 2017;49(2):243\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"513_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649\u201363.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"513_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56(Suppl 1):17\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"513_CR22","first-page":"469","volume":"62","author":"FI Kuo","year":"2009","unstructured":"Kuo FI, Ensom MHH. Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. Can J Hosp Pharm. 2009;62(6):469\u201382.","journal-title":"Can J Hosp Pharm"},{"issue":"6","key":"513_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","volume":"75","author":"Y Ikeda","year":"2004","unstructured":"Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004;75(6):587\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"513_CR24","doi-asserted-by":"crossref","unstructured":"Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure\u2013response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014;44(3):183\u201393.","DOI":"10.1016\/j.ijantimicag.2014.05.019"},{"issue":"6","key":"513_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","volume":"68","author":"I Scholz","year":"2009","unstructured":"Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"513_CR26","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1128\/AAC.00531-11","volume":"55","author":"TA Driscoll","year":"2011","unstructured":"Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, Arrieta A, Graham ML, Bradfield SM, Baruch A, Liu P. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother. 2011;55(12):5770\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"513_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2165\/00044011-200828070-00002","volume":"28","author":"S Abel","year":"2008","unstructured":"Abel S, Allan R, Gandelman K, Tomaszewski K, Webb DJ, Wood ND. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects. Clin Drug Investig. 2008;28(7):409\u201320.","journal-title":"Clin Drug Investig."},{"issue":"9","key":"513_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/phar.1631","volume":"35","author":"T Wang","year":"2015","unstructured":"Wang T, Xie J, Wang Y, Zheng X, Lei JE, Wang X, et al. Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections. Pharmacotherapy. 2015;35(9):797\u2013804.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"513_CR29","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1128\/AAC.03023-15","volume":"60","author":"LJ Huurneman","year":"2016","unstructured":"Huurneman LJ, Neely M, Veringa A, P\u00e9rez FD, Ramos-Martin V, Tissing WJ, et al. Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy. Antimicrob Agents Chemother. 2016;60(4):2336\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"513_CR30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1086\/367933","volume":"36","author":"LB Johnson","year":"2003","unstructured":"Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630\u20137.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"513_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/2047-783X-16-4-139","volume":"16","author":"M Sandherr","year":"2011","unstructured":"Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis\u2014review of the literature. Eur J Med Res. 2011;16(4):139\u201344.","journal-title":"Eur J Med Res"},{"issue":"4","key":"513_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","volume":"49","author":"F Qi","year":"2017","unstructured":"Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2017;49(4):403\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"s1","key":"513_CR33","first-page":"37","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. BJCP. 2003;56(s1):37\u201344.","journal-title":"BJCP."},{"key":"513_CR34","doi-asserted-by":"crossref","unstructured":"Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicol\u00f2 A, Cusato J, Di Perri G, D\u2019Avolio A. Evaluation of posaconazole pharmacokinetics in adult patients with invasive fungal infection. Biomedicines. 2017;5(4):E66.","DOI":"10.3390\/biomedicines5040066"},{"issue":"5","key":"513_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.dmpk.2016.05.001","volume":"31","author":"A Petitcollin","year":"2016","unstructured":"Petitcollin A, Crochette R, Tron C, Verdier MC, Boglione-Kerrien C, Vigneau C, Bellissant E, Lemaitre F. Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole. Drug Metab Pharmacokinet. 2016;31(5):389\u201393.","journal-title":"Drug Metab Pharmacokinet"},{"key":"513_CR36","doi-asserted-by":"crossref","unstructured":"Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197\u2013207.","DOI":"10.1007\/s00277-017-3196-2"},{"issue":"2","key":"513_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10096-011-1288-9","volume":"31","author":"C Eiden","year":"2012","unstructured":"Eiden C, Meniane JC, Peyri\u00e8re H, Eymard-Duvernay S, Le Falher G, Ceballos P, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis. 2012;31(2):161\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"513_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2125.2010.03680.x","volume":"70","author":"HP Lipp","year":"2010","unstructured":"Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol. 2010;70(4):471\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"513_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958\u201366.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"513_CR40","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1128\/AAC.03777-14","volume":"58","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, Br\u00fcggemann RJ, Burger DM, McLachlan AJ. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother. 2014;58(11):6879\u201385.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"513_CR41","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1086\/597110","volume":"48","author":"JW Alffenaar","year":"2009","unstructured":"Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"513_CR42","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00228-012-1212-y","volume":"68","author":"JJ Vehreschild","year":"2012","unstructured":"Vehreschild JJ, M\u00fcller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987\u201395.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"513_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1128\/AAC.01027-09","volume":"54","author":"V Kohl","year":"2010","unstructured":"Kohl V, M\u00fcller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"513_CR44","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","volume":"27","author":"G Krishna","year":"2007","unstructured":"Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27(12):1627\u201336.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"513_CR45","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1128\/AAC.06167-11","volume":"56","author":"D St\u00f6rzinger","year":"2012","unstructured":"St\u00f6rzinger D, Borghorst S, Hofer S, Busch CJ, Lichtenstern C, Hempel G, et al. Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit. Antimicrob Agents Chemother. 2012;56(8):4468\u201370.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"513_CR46","first-page":"365","volume":"20","author":"BM Sienkiewicz","year":"2016","unstructured":"Sienkiewicz BM, \u0141api\u0144ski \u0141, Wiela-Hoje\u0144ska A. Comparison of clinical pharmacology of voriconazole and posaconazole. Contemp Oncol (Pozn). 2016;20(5):365\u201373.","journal-title":"Contemp Oncol (Pozn)"},{"issue":"1","key":"513_CR47","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41598-018-20136-3","volume":"8","author":"E Leclerc","year":"2018","unstructured":"Leclerc E, Combarel D, Uzunov M, Leblond V, Funck-Brentano C, Zahr N. Prevention of invasive aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies. Sci Rep. 2018;8(1):1681.","journal-title":"Sci Rep"},{"issue":"2","key":"513_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/phar.1533","volume":"35","author":"AJ Guarascio","year":"2015","unstructured":"Guarascio AJ, Slain D. Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. Pharmacotherapy. 2015;35(2):208\u201319.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"513_CR49","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1128\/AAC.02448-13","volume":"58","author":"WK Kraft","year":"2014","unstructured":"Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"513_CR50","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/jac\/dks268","volume":"67","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, Preston RA, O\u2019Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"513_CR51","first-page":"3460892","volume":"2017","author":"M Belling","year":"2017","unstructured":"Belling M, Kanate AS, Shillingburg A, Lu X, Wen S, Shah N, et al. Evaluation of serum posaconazole concentrations in patients with hematological malignancies receiving posaconazole suspension compared to the delayed-release tablet formulation. Leuk Res Treat. 2017;2017:3460892.","journal-title":"Leuk Res Treat"},{"issue":"12","key":"513_CR52","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/jac\/dkx263","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, et al. Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017;72(12):3406\u201313.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"513_CR53","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1128\/AAC.04223-14","volume":"59","author":"WM Kersemaekers","year":"2015","unstructured":"Kersemaekers WM, van Iersel T, Nassander U, O\u2019Mara E, Waskin H, Caceres M, et al. Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects. Antimicrob Agents Chemother. 2015;59(2):1246\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"513_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-015-0348-3","volume":"75","author":"K McKeage","year":"2015","unstructured":"McKeage K. Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. Drugs. 2015;75(4):397\u2013406.","journal-title":"Drugs"},{"issue":"1","key":"513_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12941-017-0235-8","volume":"16","author":"WM Yi","year":"2017","unstructured":"Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017;16(1):60.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"513_CR56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/jof1030345","volume":"1","author":"J Li","year":"2015","unstructured":"Li J, Nguyen CT, Garcia-Diaz J. Role of new antifungal agents in the treatment of invasive fungal infections in transplant recipients: isavuconazole and new posaconazole formulations. J Fungi (Basel). 2015;1(3):345\u201366.","journal-title":"J Fungi (Basel)"},{"issue":"6","key":"513_CR57","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737\u201379.","journal-title":"Infection"},{"issue":"2","key":"513_CR58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","volume":"50","author":"AJ Ullmann","year":"2006","unstructured":"Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, T\u00f6pelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658\u201366.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"513_CR59","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1128\/AAC.01396-09","volume":"54","author":"JE Conte Jr","year":"2010","unstructured":"Conte JE Jr, DeVoe C, Little E, Golden JA. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54(9):3609\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"513_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijantimicag.2015.09.015","volume":"47","author":"L Thakuria","year":"2016","unstructured":"Thakuria L, Packwood K, Firouzi A, Rogers P, Soresi S, Habibi-Parker K, et al. A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients. Int J Antimicrob Agents. 2016;47(1):69\u201376.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"513_CR61","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/jac\/dkn409","volume":"62","author":"MJ R\u00fcping","year":"2008","unstructured":"R\u00fcping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, M\u00fcller C, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother. 2008;62(6):1468\u201370.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"513_CR62","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/bmt.2009.17","volume":"44","author":"M Reinwald","year":"2009","unstructured":"Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant. 2009;44(4):269\u201370.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"513_CR63","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1128\/AAC.03252-14","volume":"58","author":"O Blennow","year":"2014","unstructured":"Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-Serafi I, et al. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2014;58(8):4941\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"513_CR64","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1128\/AAC.01407-09","volume":"54","author":"F Farowski","year":"2010","unstructured":"Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother. 2010;54(7):2928\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"513_CR65","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1128\/AAC.00424-16","volume":"60","author":"H Zhang","year":"2016","unstructured":"Zhang H, Nguyen MH, Clancy CJ, Joshi R, Zhao W, Ensor C, et al. Pharmacokinetics of posaconazole suspension in lung transplant patients with and without cystic fibrosis. Antimicrob Agents Chemother. 2016;60(6):3558\u201362.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"513_CR66","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/myc.12339","volume":"58","author":"MH Miceli","year":"2015","unstructured":"Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses. 2015;58(7):432\u20136.","journal-title":"Mycoses"},{"issue":"2","key":"513_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/dmd.32.2.267","volume":"32","author":"A Ghosal","year":"2004","unstructured":"Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004;32(2):267\u201371.","journal-title":"Drug Metab Dispos"},{"key":"513_CR68","doi-asserted-by":"crossref","unstructured":"Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48(9):3543\u201351.","DOI":"10.1128\/AAC.48.9.3543-3551.2004"},{"issue":"8","key":"513_CR69","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/AAC.00222-12","volume":"56","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, O\u2019Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196\u2013201.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"513_CR70","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jac\/dkn401","volume":"62","author":"RY Hachem","year":"2008","unstructured":"Hachem RY, Langston AA, Graybill JR, Perfect JR, Pedicone LD, Patino H, et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother. 2008;62(6):1386\u201391.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"513_CR71","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1128\/AAC.01493-15","volume":"59","author":"AA Morris","year":"2015","unstructured":"Morris AA, Mueller SW, Rower JE, Washburn T, Kiser TH. Evaluation of sulfobutylether-\u03b2-cyclodextrin exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;59(10):6653\u201366.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"513_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007990903364657","volume":"26","author":"A Moton","year":"2010","unstructured":"Moton A, Krishna G, Ma L, O\u2019Mara E, Prasad P, McLeod J, et al. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. Curr Med Res Opin. 2010;26(1):1\u20137.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"513_CR73","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jpids\/piw087","volume":"6","author":"J McMahon","year":"2017","unstructured":"McMahon J, Th\u00e9or\u00eat Y, Autmizguine J, Bittencourt H, Tapi\u00e9ro B, Ovetchkine P. Posaconazole plasma monitoring in immunocompromised children. J Pediatr Infect Dis Soc. 2017;6(4):389\u201392.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"3","key":"513_CR74","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1128\/AAC.00454-06","volume":"51","author":"G Krishna","year":"2007","unstructured":"Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51(3):812\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"513_CR75","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/ejh.13017","volume":"100","author":"EB Vicenzi","year":"2018","unstructured":"Vicenzi EB, Calore E, Decembrino N, Berger M, Perruccio K, Carraro F, et al. Posaconazole oral dose and plasma levels in pediatric hematology\u2013oncology patients. Eur J Haematol. 2018;100(3):315\u201322.","journal-title":"Eur J Haematol"},{"issue":"10","key":"513_CR76","doi-asserted-by":"publisher","first-page":"e00569-17","DOI":"10.1128\/AAC.00569-17","volume":"61","author":"A Chin","year":"2017","unstructured":"Chin A, Pergam SA, Fredricks DN, Hoofnagle AN, Baker KK, Jain R. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob Agents Chemother. 2017;61(10):e00569-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"513_CR77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","volume":"33","author":"J Ray","year":"2011","unstructured":"Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit. 2011;33(4):387\u201392.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"513_CR78","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162\u201376.","journal-title":"J Antimicrob Chemother"},{"key":"513_CR79","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1\u201338.","journal-title":"Clin Microbiol Infect"},{"issue":"20","key":"513_CR80","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.2174\/13816128113199990332","volume":"19","author":"R Bellmann","year":"2013","unstructured":"Bellmann R. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis. Curr Pharm Des. 2013;19(20):3629\u201347.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"513_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40262-014-0139-0","volume":"53","author":"C Stockmann","year":"2014","unstructured":"Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet. 2014;53(5):429\u201354.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"513_CR82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","volume":"10","author":"BG Dekkers","year":"2016","unstructured":"Dekkers BG, Bakker M, van der Elst KC, Sturkenboom MG, Veringa A, Span LF, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10(2):51\u201361.","journal-title":"Curr Fungal Infect Rep."},{"issue":"12","key":"513_CR83","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1086\/523576","volume":"45","author":"V Nagappan","year":"2007","unstructured":"Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007;45(12):1610\u20137.","journal-title":"Clin Infect Dis"},{"key":"513_CR84","doi-asserted-by":"publisher","first-page":"295","DOI":"10.12659\/AJCR.896946","volume":"17","author":"G Panos","year":"2016","unstructured":"Panos G, Velissaris D, Karamouzos V, Matzaroglou C, Tylianakis M. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295\u2013300.","journal-title":"Am J Case Rep"},{"issue":"6","key":"513_CR85","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1592\/phco.27.6.825","volume":"27","author":"A Sansone-Parsons","year":"2007","unstructured":"Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27(6):825\u201334.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"513_CR86","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/phar.1600","volume":"35","author":"E Cho","year":"2015","unstructured":"Cho E, Chan H, Nguyen HM, Shayani S, Nakamura R, Pon D. Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. Pharmacotherapy. 2015;35(6):578\u201385.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"513_CR87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/1078155214539825","volume":"21","author":"GD Peksa","year":"2015","unstructured":"Peksa GD, Schultz K, Fung HC. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2015;21(6):409\u201315.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"513_CR88","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","volume":"55","author":"B Moriyama","year":"2012","unstructured":"Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55(4):290\u20137.","journal-title":"Mycoses"},{"issue":"2","key":"513_CR89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax\u2013posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359\u201367.","journal-title":"Clin Ther"},{"key":"513_CR90","doi-asserted-by":"crossref","unstructured":"Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure\u2013response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503\u201310.","DOI":"10.1128\/AAC.00802-12"},{"issue":"6","key":"513_CR91","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/17425255.2012.683859","volume":"8","author":"J Livermore","year":"2012","unstructured":"Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metabol Toxicol. 2012;8(6):759\u201365.","journal-title":"Expert Opin Drug Metabol Toxicol"},{"key":"513_CR92","unstructured":"Astellas Pharma US Inc. CresembaR (isavuconazonium sulfate): US prescribing information. 2015. https:\/\/www.astellas.us\/docs\/cresemba.pdf. Accessed 22 Mar 2018."},{"issue":"8","key":"513_CR93","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5414\/CP202434","volume":"54","author":"A Schmitt-Hoffmann","year":"2016","unstructured":"Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572\u201380.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"513_CR94","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"A Schmitt-Hoffmann","year":"2006","unstructured":"Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, et al. Single-ascending dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral, administrations (100, 200, and 400 milligrams) administrations of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"513_CR95","unstructured":"European Medicines Agency. Cresemba: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu. Accessed 22 Mar 2018."},{"issue":"1","key":"513_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","volume":"50","author":"A Schmitt-Hoffmann","year":"2006","unstructured":"Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy, volunteers. Antimicrob Agents Chemother. 2006;50(1):286\u201393.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"513_CR97","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/1060028015581679","volume":"49","author":"NN Pettit","year":"2015","unstructured":"Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825\u201342.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"513_CR98","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-017-2213-7","volume":"73","author":"RW Townsend","year":"2017","unstructured":"Townsend RW, Akhtar S, Alcorn H, Berg JK, Kowalski DL, Mujais S, et al. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017;73(3):669\u201378.","journal-title":"Eur J Clin Pharmacol"},{"key":"513_CR99","doi-asserted-by":"publisher","unstructured":"Wilby KJ. A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole. Eur J Drug Metab Pharmacokinet. 2018;43(3):281\u201390. https:\/\/doi.org\/10.1007\/s13318-017-0445-7.","DOI":"10.1007\/s13318-017-0445-7"},{"key":"513_CR100","doi-asserted-by":"crossref","unstructured":"Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60:5483\u201391.","DOI":"10.1128\/AAC.02819-15"},{"key":"513_CR101","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1128\/AAC.00514-16","volume":"60","author":"LL Kovanda","year":"2016","unstructured":"Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, Hope WW. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60:4568\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"513_CR102","first-page":"79","volume":"9","author":"MA Donnelley","year":"2016","unstructured":"Donnelley MA, Zhu ES, Thompson GR III. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79\u201386.","journal-title":"Infect Drug Resist."},{"issue":"7","key":"513_CR103","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR III, VITAL and FungiScope Mucormycosis Investigators, et al. Isavuconazole treatment for mucormycosis: open-label trial and contemporaneous case\u2013control analysis. Lancet Infect Dis. 2016;16(7):828\u20138371.","journal-title":"Lancet Infect Dis."},{"key":"513_CR104","doi-asserted-by":"crossref","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","DOI":"10.1016\/S0140-6736(15)01159-9"},{"issue":"1","key":"513_CR105","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ijpp.12302","volume":"25","author":"D Murrell","year":"2017","unstructured":"Murrell D, Bossaer JB, Carico R, Harirforoosh S, Cluck D. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections. Int J Pharm Pract. 2017;25(1):18\u201330.","journal-title":"Int J Pharm Pract."},{"issue":"1","key":"513_CR106","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"AH Groll","year":"2017","unstructured":"Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, et al. Pharmacokinetic assessment of drug\u2013drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76\u201385.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"513_CR107","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.283","volume":"6","author":"A Desai","year":"2017","unstructured":"Desai A, Yamazaki T, Dietz AJ, Kowalski D, Lademacher C, Pearlman H, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug\u2013drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):86\u201392.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"513_CR108","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1128\/AAC.02931-15","volume":"60","author":"VJ Lempers","year":"2016","unstructured":"Lempers VJ, van den Heuvel JJ, Russel FG, Aarnoutse RE, Burger DM, Br\u00fcggemann RJ, et al. Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016;60(6):3372\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"513_CR109","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1179\/joc.2008.20.6.661","volume":"20","author":"A De Sarro","year":"2008","unstructured":"De Sarro A, La Camera E, Fera MT. New and investigational triazole agents for the treatment of invasive fungal infections. J Chemother. 2008;20(6):661\u201371.","journal-title":"J Chemother"},{"issue":"4","key":"513_CR110","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.3314\/mmj.16-00006","volume":"57","author":"H Yamaguchi","year":"2016","unstructured":"Yamaguchi H. Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis. Med Mycol J. 2016;57(4):E93\u2013110.","journal-title":"Med Mycol J"},{"issue":"2","key":"513_CR111","first-page":"165","volume":"11","author":"AC Pasqualotto","year":"2010","unstructured":"Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs. 2010;11(2):165\u201374.","journal-title":"Curr Opin Investig Drugs"},{"issue":"Suppl 1","key":"513_CR112","doi-asserted-by":"publisher","first-page":"i19","DOI":"10.1093\/jac\/dkm428","volume":"61","author":"AC Pasqualotto","year":"2008","unstructured":"Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother. 2008;61(Suppl 1):i19\u201330.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"513_CR113","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4155\/cli.11.137","volume":"1","author":"C Girmenia","year":"2011","unstructured":"Girmenia C, Finolezzi E. New-generation triazole antifungal drugs: review of the phase II and III trials. Clin Investig. 2011;1(11):1577\u201394.","journal-title":"Clin Investig"},{"key":"513_CR114","first-page":"838","volume":"40","author":"SJ Olsen","year":"2000","unstructured":"Olsen SJ, Mummaneni V, Rolan P, Norton J, Grasela DM. Ravuconazole single ascending oral dose study in healthy subjects. ICAAC Abstr. 2000;40:838.","journal-title":"ICAAC Abstr"},{"key":"513_CR115","unstructured":"Marino M, Mummaneni V, Norton J, Hadjilambris O, Pierce P. Ravuconazole exposure\u2013response relationship in HIV\u2009+\u2009patients with oropharyngeal candidiasis (abstract J-1622). In: American Society for Microbiology, editor. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 393."},{"key":"513_CR116","unstructured":"Beale M, Queiroz-Telles F, Banhegyi D, Li N, Pierce PF. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis (abstract J-1621). In: American Society for Microbiology, editor. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 392."},{"issue":"2","key":"513_CR117","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/0091270005283462","volume":"46","author":"JH Yan","year":"2006","unstructured":"Yan JH, Marino MR, Smith RA, Kanamaluru V, O\u2019Mara EM, Grasela DM. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol. 2006;46(2):193\u2013200.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"513_CR118","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/myc.12727","volume":"61","author":"M Hoenigl","year":"2018","unstructured":"Hoenigl M, Prattes J, Neumeister P, W\u00f6lfler A, Krause R. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: an illustrative case study. Mycoses. 2018;61(3):201\u20135.","journal-title":"Mycoses"},{"key":"513_CR119","doi-asserted-by":"publisher","unstructured":"Perfect JR, Cornely OA, Heep M, Ostrosky-Zeichner L, Mullane KM, Maher R, et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial. Mycoses. 2018;61(7):420\u20139. https:\/\/doi.org\/10.1111\/myc.12769\n                           (Epub ahead of print).","DOI":"10.1111\/myc.12769"},{"issue":"3","key":"513_CR120","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","volume":"19","author":"Y Hamada","year":"2013","unstructured":"Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):381\u201392.","journal-title":"J Infect Chemother."},{"issue":"1","key":"513_CR121","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","volume":"18","author":"L Chen","year":"2018","unstructured":"Chen L, Wang Y, Zhang T, Li Y, Meng T, Liu L, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential, analysis. BMC Infect Dis. 2018;18(1):155.","journal-title":"BMC Infect Dis"},{"key":"513_CR122","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jpba.2017.07.040","volume":"145","author":"G Fatiguso","year":"2017","unstructured":"Fatiguso G, Favata F, Zedda I, De Nicol\u00f2 A, Cusato J, Avataneo V, et al. A simple high performance liquid chromatography\u2013mass spectrometry method for therapeutic drug monitoring of isavuconazole and four other antifungal drugs in human plasma samples. J Pharm Biomed Anal. 2017;145:718\u201324.","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"513_CR123","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1128\/AAC.00229-16","volume":"60","author":"NP Wiederhold","year":"2016","unstructured":"Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, et al. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis. Antimicrob Agents Chemother. 2016;60(9):5600\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"513_CR124","doi-asserted-by":"publisher","first-page":"232470961877047","DOI":"10.1177\/2324709618770","volume":"6","author":"R Jariwal","year":"2018","unstructured":"Jariwal R, Heidari A, Sandhu A, Patel J, Shoaepour K, Natarajan P, et al. Granulomatous invasive Aspergillus flavus infection involving the nasal sinuses and brain. J Investig Med High Impact Case Rep. 2018;6:2324709618770473. https:\/\/doi.org\/10.1177\/2324709618770.","journal-title":"J Investig Med High Impact Case Rep."},{"issue":"10","key":"513_CR125","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.jocn.2014.05.004","volume":"21","author":"JR Ellenbogen","year":"2014","unstructured":"Ellenbogen JR, Waqar M, Denning DW, Cooke RP, Skinner DW, Lesser T, Javadpour M. Posaconazole responsive cerebral aspergillosis in an immunocompetent adult. J Clin Neurosci. 2014;21(10):1825\u20137.","journal-title":"J Clin Neurosci."},{"key":"513_CR126","doi-asserted-by":"publisher","unstructured":"Tsakiri S, Aneji C, Domonoske C, Mazur L, Benjamin DK Jr, Wootton SH. Voriconazole treatment for an infant with intractable Candida glabrata meningitis. Pediatr Infect Dis J. 2018;37(10):999\u20131001. https:\/\/doi.org\/10.1097\/inf.0000000000002073\n                           (Epub ahead of print).","DOI":"10.1097\/inf.0000000000002073"},{"key":"513_CR127","doi-asserted-by":"publisher","unstructured":"Kim T, Jancel T, Kumar P, Freeman AF. Drug\u2013drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther. 2015;40(5):609\u201311. https:\/\/doi.org\/10.1111\/jcpt.12308\n                           (Epub ahead of print).","DOI":"10.1111\/jcpt.12308"},{"key":"513_CR128","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2018.05.009","volume":"72","author":"T Wang","year":"2018","unstructured":"Wang T, Yan M, Tang D, Xue L, Zhang T, Dong Y, et al. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child\u2013Pugh class B and C cirrhosis: a multicenter study. Int J Infect Dis. 2018;72:49\u201354.","journal-title":"Int J Infect Dis."},{"key":"513_CR129","doi-asserted-by":"publisher","unstructured":"Yamada T, Imai S, Koshizuka Y, Tazawa Y, Kagami K, Tomiyama N, et al. Necessity for a significant maintenance dosage reduction of voriconazole in patients with severe liver cirrhosis (Child\u2013Pugh class C). Biol Pharm Bull. 2018;41(7):1112\u20138. https:\/\/doi.org\/10.1248\/bpb.b18-00164\n                           (Epub ahead of print).","DOI":"10.1248\/bpb.b18-00164"},{"key":"513_CR130","unstructured":"Merck Sharp & Dohme Limited. Noxafil 300\u00a0mg concentrate for solution for infusion. Summary of product characteristics. 2017. http:\/\/www.medicines.org.uk\/emc\/product\/3435\/smpc. Accessed 14 Apr 2018."},{"key":"513_CR131","unstructured":"Pfizer Limited. Cresemba 200\u00a0mg powder for concentrate for solution for infusion. Summary of product characteristics. 2017. http:\/\/www.medicines.org.uk\/emc\/product\/5069\/smpc. Accessed 14 Apr 2018."},{"issue":"1","key":"513_CR132","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13613-018-0373-y","volume":"8","author":"DY Fuhrman","year":"2018","unstructured":"Fuhrman DY, Kane-Gill S, Goldstein SL, Priyanka P, Kellum JA. Acute kidney injury epidemiology, risk factors, and outcomes in critically ill patients 16\u201325\u00a0years of age treated in an adult intensive care unit. Ann Intensive Care. 2018;8(1):26.","journal-title":"Ann Intensive Care."},{"issue":"4","key":"513_CR133","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/FTD.0b013e3182205d93","volume":"33","author":"J Radej","year":"2011","unstructured":"Radej J, Krouzecky A, Stehlik P, Sykora R, Chvojka J, Karvunidis T, et al. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration. Ther Drug Monit. 2011;33(4):393\u20137.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"513_CR134","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1086\/377131","volume":"37","author":"I Lutsar","year":"2003","unstructured":"Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728\u201332.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"513_CR135","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1128\/AAC.03050-14","volume":"58","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, L\u00f3pez-Jim\u00e9nez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother. 2014;58(10):5758\u201365.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"513_CR136","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1128\/AAC.02686-13","volume":"58","author":"J Maertens","year":"2014","unstructured":"Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother. 2014;58(7):3610\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"513_CR137","doi-asserted-by":"crossref","unstructured":"Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166\u201372.","DOI":"10.1128\/AAC.48.6.2166-2172.2004"},{"issue":"7","key":"513_CR138","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00432-017-2369-7","volume":"143","author":"M D\u00f6ring","year":"2017","unstructured":"D\u00f6ring M, Stanchi KM, Queudeville M, Feucht J, Blaeschke F, Schlegel P, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2017;143(7):1281\u201392.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"513_CR139","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1517\/17425255.2012.683859","volume":"8","author":"J Livermore","year":"2012","unstructured":"Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012;8(6):759\u201365.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"513_CR140","first-page":"Abs F-817","volume":"42","author":"Y Ueda","year":"2002","unstructured":"Ueda Y, Barbour N, Bronson JJ, Connolly TP, Dali M, Gao Q, et al. BMS-379224, a watersoluble prodrug of ravuconazole. Intersci Conf Antimicrob Agents Chemother. 2002;42:Abs F-817.","journal-title":"Intersci Conf Antimicrob Agents Chemother"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0513-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-018-0513-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0513-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:28:33Z","timestamp":1659097713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-018-0513-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,9]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0513-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]},"assertion":[{"value":"3 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None of the authors has any conflict of interest in regard to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript was partially financed by a grant (no. 175007) given by the Serbian Ministry of Education, Science, and Technology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}